Physician

William Joseph Jawien, MD

According to 2025 Medicare claims, William Jawien, MD (NPI: 1417904020) practices medical oncology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Jawien's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 870 traditional Medicare patients, billed 287,870 HCPCS/CPT codes, and received $3,768,790 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,728 prescription claims across 228 beneficiaries totaling $4,387,868 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 40 claims. Open Payments data shows 110 records totaling $2,316. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,592,480 to $3,768,790. Similarly, Part D prescription costs have moved sharply higher in recent years, from $717,169 to $4,387,868. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,287 and ending at $2,105.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	787	244,002	$1,592,480
2016	721	244,825	$1,774,591
2017	709	280,159	$2,107,015
2018	701	283,426	$1,837,267
2019	518	268,480	$1,565,842
2020	933	326,141	$2,583,452
2021	1,026	370,927	$3,708,068
2022	755	300,676	$3,073,192
2023	978	379,209	$4,754,393
2024	870	287,870	$3,768,790

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	130	927	$717,169
2016	140	926	$954,329
2017	152	1,005	$1,354,218
2018	148	1,038	$1,791,078
2019	155	1,171	$2,761,890
2020	174	1,215	$2,688,394
2021	173	1,231	$3,025,983
2022	189	1,224	$3,708,171
2023	213	1,525	$4,884,775
2024	228	1,728	$4,387,868

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	30	$9,086
2017	N/R	29	$6,236
2018	N/R	56	$7,403
2019	N/R	23	$1,828
2020	N/R	22	$380
2021	N/R	134	$11,355
2022	N/R	121	$3,911
2023	N/R	102	$11,407
2024	N/R	40	$2,971

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	425	1,203	$97
96372	Injection of drug or substance under skin or into muscle	257	928	$11
80053	Blood test, comprehensive group of blood chemicals	348	1,026	$10
36415	Insertion of needle into vein for collection of blood sample	391	1,484	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	396	1,556	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	42	1,260	$725,303
Lenalidomide	Lenalidomide	38	1,064	$574,623
Ibrance	Palbociclib	30	840	$464,109
Braftovi	Encorafenib	12	360	$182,114
Mektovi	Binimetinib	12	360	$178,677

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4224	Parenteral nutrition administration kit, per day	N	N/R	12	$1,944
B4220	Parenteral nutrition supply kit; premix, per day	N	N/R	12	$622
K0001	Standard wheelchair	Y	N/R	16	$405

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	110	$2,316	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for William Joseph Jawien, MD?

Tedicare shows public-source Medicare data for William Joseph Jawien, MD (NPI 1417904020), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does William Joseph Jawien, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to William Joseph Jawien, MD?

William Joseph Jawien, MD is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does William Joseph Jawien, MD have Open Payments data?

William Joseph Jawien, MD has 110 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.